HCPLive

~40 Percent of Cancer Patients Receive Opioids at End of Life

 
THURSDAY, Dec. 13 (HealthDay News) -- For patients with one of five common cancers, 43.6 percent receive at least one prescription of opioids in the last three months of life, according to a study published in the Dec. 10 issue of the Journal of Clinical Oncology.

Irene J. Higginson, B.M.B.S., Ph.D., and Wei Gao, Ph.D., from King's College London, used data from the United Kingdom General Practice Research Database to examine opioid prescribing rates in the last three months of life in a cohort of 29,825 patients diagnosed with lung, colorectal, female breast, prostate, and head and neck cancers. All patients died between 2000 and 2008.

The researchers found that 43.6 percent of patients received at least one prescription of opioids during the last three months of life, including the most prescribed opioids: 33.4 percent morphine, 11.6 percent diamorphine, and 10.2 percent fentanyl family. For opioids predominant during specific time periods, especially oxycodone, prescription rates increased over time. Compared with patients younger than 50 years, patients older than 60 years had significantly lower chances of receiving opioids, even after adjustment for comorbidity (prevalence ratio range, 0.14 to 0.78). Compared with men, women were slightly but significantly more likely to receive any opioid (prevalence ratio, 1.07). Compared with prostate cancers, morphine and diamorphine were more commonly prescribed for lung and colorectal cancers, while fentanyl family drugs were more commonly prescribed for head and neck cancers.

"We found an encouraging increasing trend of opioid prescribing by general practitioners in the United Kingdom for patients with cancer who are in the last three months of life," the authors write. "However, people older than age 60 years were significantly underprescribed opioids and should be targeted for improvement in their end-of-life cancer care."
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 
 
 

Most Popular

Recommended Reading

Making the transition from transfemoral to transradial access may provide longterm benefits for acute coronary syndrome patients, but changing years of training to the newer method also figures to be a longterm project for the cardiac community.
For patients with acute coronary syndrome there has been one longstanding treatment method which doctors have used for many years. In recent years interventional cardiologists have been looking at whether a fresh approach might be best for this patient group.
What is currently considered to be the “gold standard” for post-shoulder surgery pain management may not be as effective as what once was believed.
Though current cell phones are not up to par, soon, mobile devices like smart phones can serve as cardiac monitors, according to a clinical review published in JAMA Internal Medicine.
$vAR$